Anti-HIV microbicide development: Targeting the virus is the key

Future Virology

Volumn 6, Issue 5, 2011, Pages 553-556

  O'Keefe, Barry R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

antiviral; drug development; HIV; microbicide; PrEP

Indexed keywords

CARBOPOL 974P; CYANOVIRIN N; DAPIVIRINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MARAVIROC; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; POLYANION; VIRUS ENVELOPE PROTEIN;

DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; NICOTIANA BENTHAMIANA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUAL TRANSMISSION; TREATMENT RESPONSE; VIRUS ATTACHMENT; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 79957605229     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.38     Document Type: Review

References (29)

1. McNeil DG: New lines of attack in H.I.V. prevention. New York Times, NY, USA, 8 November (2010).
2. Karim QA, Karim SS, Frohlich JA et al.: Effectiveness and safety of Tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010).
3. Grant RM, Lama JR, Anderson PL et al.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587-2599 (2010).
4. Van Damme L, Ramjee G, Alary M et al.: Effectiveness of Col-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomized controlled trial. Lancet 360, 971-977 (2002). (Pubitemid 35284107)
5. Peterson L, Nanda K, Opoku BK et al.: SAAVY (C31G) vaginal gel for prevention of HIV infection in women: a Phase III, double-blind, randomized, placebocontrolled trial in Ghana. PLoS ONE 2, E1312 (2007).
6. Skoler-Karpoff S, Ramgee G, Ahmed K et al.: Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372, 1977-1987 (2008).
7. VanDamme L, Govinden R, Mirembe F et al.: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359, 463-472 (2008).
8. Abdool Karim SS, Coletti A, Richardson B et al.: Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25(7), 957-966 (2011).
9. Cohen J: At last, vaginal gel scores victory against HIV. Science 329, 374-375 (2010).
10. Burns DN, Dieffenbach CW, Vermund SH: Rethinking prevention of HIV type 1 infection. HIV/AIDS 51, 725-731 (2010).
11. Cohen J: A powerful and perplexing new HIV prevention tool. Science 330, 1298-1299 (2010).
12. Doncel GF, Clark MR: Preclinical evaluation of anti-HIV microbicide products: new models and biomarkers. Antiviral Res. 88(Suppl. 1), S10-S18 (2010).
13. Borkow G, Barnard J, Nguyen TM et al.: Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J. Virol. 71, 3023-3030 (1997). (Pubitemid 27119946)
14. Patton DN, Cosgrove Sweener YT, Balkus E et al.: Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. Antimicrob. Agents Chemother. 51, 1608-1615 (2007).
15. Fletcher PS, Elliot J, Grivel J-C et al.: Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 20, 1237-1245 (2006). (Pubitemid 44030371)
16. Fletcher P, Harmon S, Azijn H et al.: Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 53, 487-495 (2009).
17. Nel AM, Coplan P, van de Wijgert et al.: Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 23, 1531-1538 (2009).
18. Lederman MM, Veazey RS, Offord R et al.: Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306, 485-487 (2004). (Pubitemid 39372448)
19. Gaertner H, Cerini F, Escola J-M et al.: Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc. Natl Acad. Sci. USA 105, 17706-17711 (2008).
20. Boyd MR, Gustafson KR, McMahon JB et al.: Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob. Agents Chemother. 41, 1521-1530 (1997). (Pubitemid 27289680)
21. Bolmstedt AJ, O'Keefe BR, Shenoy SR et al.: Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol. Pharmacol. 59, 949-954 (2001). (Pubitemid 32381571)
22. Tsai CC, Emau P, Jiang Y et al.: Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res. Hum. Retroviruses 19, 535-541 (2003). (Pubitemid 36900571)
23. Tsai CC, Emau P, Jiang Y et al.: Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retroviruses. 20, 11-18 (2004). (Pubitemid 38147172)
24. Liu X, Lagenaur LA, Simpson DA et al.: Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob. Agents Chemother. 50, 3250-3259 (2006). (Pubitemid 44527495)
25. Xu Q: Bioengineered lactobacilli as next generation probiotics. Presented at: Microbicides 2010: Probiotics: the Potential for a Live Microbicide. Pittsburgh, PA, USA, 22 May 2010.
26. Mori T, O'Keefe BR, Sowder RC 2nd et al.: Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J. Biol. Chem. 280, 9345-9353 (2005). (Pubitemid 40409628)
27. Emau P, Tian B, O'Keefe BR et al.: Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J. Med. Primatol. 36, 244-253 (2007). (Pubitemid 47103488)
28. O'Keefe BR, Vojdani F, Buffa V et al.: Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl Acad. Sci. USA 106, 6099-6104 (2009).
29. Morris G, Wiggins R, Woodhall S et al.: A Phase 1 randomized controlled trial of a triple anti-HIV-1 monoclonal antibody vaginal microbicide. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011.